Rheumatology volume 54 Supplement 2 May 2015 www.rheumatology.oxfordjournals.org

abstracts BRITISH SOCIETY FOR PAEDIAtRIC AND ADOLESCENT RHEUMATOLOGY ANNUAL CONFERENCE 2014 LEEDS, UK, 25–26 SEPTEMBER 2014

RHE_54_Supplement_2.indd 1

4/24/2015 4:54:47 PM

The British Society for Paediatric and Adolescent Rheumatology Annual Conference 2014 Leeds, UK, 25–26 September 2014

# 2015 British Society for Rheumatology All rights reserved. No part of this publication may be reproduced, translated, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the British Society for Rheumatology. Typeset by Cenveo Publisher Services, Bangalore, India Printed by Bell and Bain Ltd, Glasgow, UK

Rheumatology Volume 54 Supplement 2 May 2015

CONTENTS British Society for Paediatric and Adolescent Rheumatology Annual Conference 2014 INTRODUCTION Abstracts from the 2014 Annual Conference of the British Society of Paediatric and Adolescent Rheumatology Valentina Leone and Mark Wood on behalf of BSPAR 2014 organizing committee

ii1

ORAL PRESENTATIONS OP1. Clinically inactive disease in JDM: a proposed revision to the Pediatric Rheumatology International Trials Organisation criteria Beverley Almeida, Katie Arnold, Raquel Campanilho-Marques, Lucy Wedderburn, Clarissa Pilkington and Kiran Nistala, on behalf of Juvenile Dermatomyositis Research Group

ii2

OP2. The efficacy of a multidisciplinary intervention strategy for the treatment of benign joint hypermobility syndrome in childhood: a randomized, single centre parallel group trial (The BENDY Study) Peter Bale, Vicky Easton, Holly Bacon, Emma Jerman, Kate Armon and Alex MacGregor

ii2

OP3. Developing a urinary biomarker panel for monitoring lupus nephritis disease activity Eve M. D. Smith, Rachel Corkhill, Angela Midgley, Louise Watson, Caroline Jones, Stephen D. Marks, Kjell Tullus, Clarissa Pilkington and Michael W. Beresford

ii3

OP4. Enthesitis-related arthritis in adolescence: disease phenotype in a large cohort Corinne Fisher, Linda Suffield, Anna Radziszewska, Debajit Sen and Yiannis Ioannou

ii3

POSTER PRESENTATIONS JUVENILE IDIOPATHIC ARTHRITIS PP1. Factors associated with choice of first biologic among children with JIA: a combined analysis from two UK paediatric biologic registers Lianne Kearsley-Fleet, Rebecca Davies, Eileen Baildam, Michael W. Beresford, Helen E. Foster, Taunton R. Southwood, Wendy Thomson and Kimme L. Hyrich, on behalf of the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study and the Biologics for Children with Rheumatic Diseases study

ii5

PP2. Predicting treatment response to etanercept in JIA: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study Lianne Kearsley-Fleet, Rebecca Davies, Mark Lunt, Taunton R. Southwood and Kimme L. Hyrich, on behalf of the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

ii5

PP3. Standardized mortality rates are increased in patients with severe JIA Rebecca Davies, Taunton R. Southwood, Lianne Kearsley-Fleet, Mark Lunt and Kimme L. Hyrich, on behalf of the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

ii6

PP4. Treatment prescribing patterns in a cohort of patients with JIA: data from the Childhood Arthritis Prospective Study Rebecca Davies, Roberto Carrasco, Helen E Foster, Eileen Baildam, Alice Chieng, Joyce E Davidson, Yiannakis Ioannou, Lucy Wedderburn, Wendy Thomson and Kimme Hyrich, on behalf of the Childhood Arthritis Prospective Study

ii6

PP5. Evaluation of an NHS JIA treatment pathway compared with published international recommendations Katherine Green, Nicola Freeman, Taunton Southwood, Penny Davis and Marinka Twilt

ii7

www.rheumatology.oxfordjournals.org

PP6. Felty’s syndrome in rheumatoid factor positive polyarticular juvenile idiopathic arthritis: the role of rituximab Laura E. Brown, Sunil Sampath, Fiona Ryan, Clare E. Pain, Liza J. McCann, Gavin Cleary, Michael W. Beresford and Eileen M. Baildam

ii7

PP7. Cervical-spine involvement in JIA: a single-centre study Kamran Mahmood, Amjad Khan, Jacqui Clinch and Manigandan Subramanyam Thayagarajan

ii7

PP8. Outcome following intra-articular steroid injection in JIA, according to MSUS findings Amany Tadrous, Catherine Mc Allister, Jenny Wyatt and Madeleine Rooney

ii8

PP9. Clinical and radiological features of Down’s arthropathy Charlene Foley, Emma MacDermott and Orla Killeen

ii8

PP10. Evaluation of skin temperature using liquid crystal and infrared thermometers in children attending specialist paediatric rheumatology clinics Daniel Hawley, Amaka C. Offiah, Samuel J. Hawley and Derek Burke

ii9

PP11. Assessment of radiographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year data from TENDER Eileen Baildam, Angelo Ravelli, Clara Malattia, Nicola Ruperto, Elena Palmisani, Silvia Pederzoli, Angela Pistorio, Hermine I. Brunner, Rube´n Cuttica, Inmaculada Calvo Penades, Stella Maris Garay, Despina Eleftheriou, Carine Wouters, Jianmei Wang, Clare Devlin, Daniel J. Lovell, Alberto Martini and Fabrizio De Benedetti, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

ii9

PP12. Predicting pain over time in JIA: results from the Childhood Arthritis Prospective Study Amir Rashid, Kate Holliday, Lis Cordingley, Roberto Carrasco, Bo Fu, Helen E. Foster, Eileen M. Baildum, Alice Chieng, Joyce E. Davidson, Lucy Wedderburn, Kimme L. Hyrich and Wendy Thomson

ii10

PP13. Intravenous methotrexate: a single-centre experience Ellen Mosley, Kishore Warrier, Karen Kelsall, Elizabeth Stretton and Satyapal Rangaraj

ii10

CONNECTIVE TISSUE DISEASES AND VASCULITIS PP14. Comparison of the utility and validity of three scoring tools to detect skin disease in patients with juvenile dermatomyositis Raquel Campanilho-Marques, Beverley Almeida, Katie Arnold, Kiran Nistala, Clarissa A. Pilkington and Lucy R. Wedderburn, on behalf of the Juvenile Dermatomyositis Research Group (JDRG)

ii11

PP15. Juvenile-onset systemic lupus erythematosus with overlap features of ANCA-associated vasculitis : a case report Laura E. Brown, Sunil Sampath, Fiona Ryan, Gavin Cleary, Liza McCann, Clare Pain, Michael Beresford, MG Semple, Jo McPartland, Arti Bakshi and Eileen Baildam

ii11

PP16. The role of etanercept in juvenile dermatomyositis in children Katherine Green, Roseanne Wilshire, Taunton Southwood, Penny Davis and Marinka Twilt

ii12

AUTO-INFLAMMATORY CONDITIONS/UVEITIS/OTHER PP17. Primary hypertrophic osteoarthropathy: the utility of MRI in assessing inflammation: a clinicoradiological correlation Tania Amin, Brook Adams, Jeanette Kraft and Valentina Leone

ii13

PP18. A case series of chronic non-bacterial osteomyelitis Ayesha Islam, Sarah Qasim, Tania Amin, Mark Wood and Valentina Leone

ii13

PP19. Evaluation of the use of combined treatment regimens involving methotrexate and mycophenolate mofetil in the Sheffield paediatric uveitis service Sarah Gormley, Jessy Choi and Daniel P. Hawley

ii14

PP20. Bruising, bleeding and recurrent compartment syndrome: a case of Gardner–Diamond syndrome (autoerythrocyte sensitization syndrome)? Ethan Sen, Kamran Mahmood and Jacqui Clinch

ii15

AUDIT AND QUALITY IMPROVEMENT PP21. Patient attitudes to new national on-line paediatric rheumatology transition documentation Katie Patterson, Cath Thwaites, Alex Tabor and Jon Packham

ii15

PP22. Reducing barriers to transition: entonox analgesia for joint injections in adult services Rachel Tattersall, Maria Forsythe and Anne-Marie McMahon

ii15

PP23. Multicentre audit of disease activity assessment in JIA: JIA Topic Specific Group 2014 Flora McErlane, Gillian Armitt, Andrew Smith, Mark Friswell, Helen Foster and Wendy Thomson

ii16

PP24. Evaluation of the effectiveness of specialist occupational therapy input in schools attended by children and young people with juvenile idiopathic arthritis Michelle Loveley, Muthana Al-Obaidi, AnneMarie McMahon and Daniel P Hawley

ii16

www.rheumatology.oxfordjournals.org

PP25. Investigating the feasibility and acceptability of a newly developed iPad application (app) for measuring pain in juvenile idiopathic arthritis patients Pauline Tapping, Amir Rashid, Alice Chieng, Rachel Calam, Lis Cordingley and Wendy Thomson

ii17

PP26. Internet access and utilization of adolescents attending a National Centre for Paediatric Rheumatology Derek Deely, Orla Killeen and Emma Jane MacDermott

ii17

BASIC SCIENCE PP27. Tumour necrosis factor-a levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy Anna Radziszewska, Corinne Fisher, Linda Suffield, Geevithan Kumaran, Debajit Sen and Yiannis Ioannou

ii18

PP28. Myeloid-related proteins 8 and 14: potential biomarkers of disease activity of arthritis in children with trisomy 21 Charlene Foley, Emma MacDermott and Orla Killeen

ii18

Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the Organizers for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnoses and drug doses should be made.

www.rheumatology.oxfordjournals.org

RHEUMATOLOGY

Introduction Abstracts from the 2014 Annual Conference of the British Society of Paediatric and Adolescent Rheumatology The British Society of Paediatric and Adolescent Rheumatology (BSPAR) is a registered charity and a specialist society linked to the British Society for Rheumatology (BSR) and to the Royal College of Paediatric and Child Health (RCPCH). Its membership is open to all health professionals involved in the care of children and adolescents with rheumatological conditions within paediatric rheumatology departments and allied clinical networks. The BSPAR membership currently stands at 379 members. The main aim of BSPAR is to advance paediatric rheumatology care in the UK and Ireland by raising the standard of clinical care, enhancing the quality of training, supporting research and promoting patients’ and parents’ representation and engagement. Information on the work of BSPAR including policy documents, clinical guidelines and reports summarizing the work of the various subcommittees and professionals’ groups feeding into the society is available on the BSPAR website. A national parent group is independently run by

parents and careers and its work is highlighted in the Parent group page within the BSPAR website. This year’s annual meeting was held in the magnificent Leeds Town Hall and was attended by 230 delegates. The meeting ran over two days and received very good feedback praising the variety and quality of the scientific programme and networking opportunities. The annual meeting was preceded by a very successful Research Day organized by Dr Madeleine Rooney offering trainees and young investigators an opportunity to present their research work. Forty-four abstracts were received and peer-reviewed by a nominated committee of four reviewers and we are pleased to publish the 32 top ranking abstracts in this supplement of Rheumatology. Dr Valentina Leone and Dr Mark Wood on behalf of BSPAR 2014 organizing committee. doi: 10.1093/rheumatology/kev007

! The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected]

ii1

ORAL PRESENTATIONS OP1. CLINICALLY INACTIVE DISEASE IN JDM: A PROPOSED REVISION TO THE PEDIATRIC RHEUMATOLOGY INTERNATIONAL TRIALS ORGANISATION CRITERIA Beverley Almeida1,2, Katie Arnold2, Raquel Campanilho-Marques1,2, Lucy Wedderburn2,3, Clarissa Pilkington1 and Kiran Nistala4, on behalf of Juvenile Dermatomyositis Research Group 1 Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, 2Infection, Inflammation and Rheumatology Section, University College London Institute of Child Health, 3Arthritis Research UK Centre for Adolescent Rheumatology, UCL, UCLH, GOSH NHS Trust, 4Centre for Rheumatology, University College London, UK Correspondence to: Beverley Almeida. E-mail: [email protected] Background: The Pediatric Rheumatology International Trials Organisation (PRINTO) established criteria to classify clinically inactive JDM patients by meeting at least three out of four conditions: CK U/L, CMAS, MMT8 and physicians global visual analogue scale (VAS) 2. Only VAS includes skin or other organ involvement. Aims: To demonstrate the prevalence of clinical inactivity in the UK JDM Cohort and Biomarker Study using the PRINTO criteria and to identify whether skin disease is still present. Methods: Data entries (DEs) from patients who met Bohan–Peter criteria were assessed using the PRINTO criteria. Using the rules stipulating 3 of 4 criteria are required, DEs were divided based on the criteria that was not met. Each entry was analysed to determine whether skin disease was present or absent. Results: 682 DEs (321 patients) were identified as clinically inactive. 255 (37.4%) of these DEs (119 patients) met all four criteria (Table 1). 427 of the total DEs (202 patients) met three of four criteria. Of these, 320 (74.9%) were clinically inactive based on the three muscle criteria (VAS was not met). 61.6% of this group had ongoing skin rash present. Among the 107 remaining DEs, which were clinically inactive by three criteria of which one was VAS, the frequency of skin changes was lower. The differences between the three groups were significant in terms of rash (2 111.5, P < 0.0001), nailfold changes (2 65.5, P < 0.0001) and calcinosis (2 22.07, P < 0.0001). Conclusion: This study is one of the first to test the PRINTO criteria in an independent cohort of JDM patients. When clinically inactive disease is defined without VAS, there is a greater frequency of skin disease. As a revision, we propose that VAS should be included as an essential criterion together with two of the three muscle criteria. This would prevent skin disease being overlooked in the clinical assessment. Disclosure statement: The authors have declared no conflicts of interest. doi: 10.1093/rheumatology/keu490

TABLE 1 Frequency of skin changes in JDM patients meeting PRINTO criteria, number of episodes (%) No. of criteria met

Rash

Nailfold changes

All four criteria met (255 DEs, n ¼ 119) Three criteria met, but VAS not met (320 DEs, n ¼ 131) Three criteria met of which one was VAS (107 DEs, n ¼ 71)

54 (21.2) 197 (61.6)

27 (10.5) 114 (35.6)

19 (7.5) 60 (18.8)

25 (23.3)

9 (8.4)

6 (5.6)

DEs: number of data entries; n: number of patients.

Calcinosis

OP2. THE EFFICACY OF A MULTIDISCIPLINARY INTERVENTION STRATEGY FOR THE TREATMENT OF BENIGN JOINT HYPERMOBILITY SYNDROME IN CHILDHOOD: A RANDOMIZED, SINGLE CENTRE PARALLEL GROUP TRIAL (THE BENDY STUDY) Peter Bale1, Vicky Easton1, Holly Bacon1, Emma Jerman2, Kate Armon1 and Alex MacGregor1,3 1 Paediatric Rheumatology, Jenny Lind Children’s Department, Norfolk and Norwich University Hospital, 2senSI Ltd and 3Norwich Medical School, University of East Anglia, Norwich, UK Correspondence to: Peter Bale. E-mail: [email protected] Background: Joint hypermobility is common in childhood and can be associated with musculoskeletal pain and dysfunction. Current management is delivered by a multidisciplinary team but evidence of efficacy is limited. Aims: This clinical trial aimed to determine whether a structured multidisciplinary intervention resulted in improved clinical outcomes compared with standard care. Methods: A prospective randomized, single centre parallel group trial comparing an 8-week individualized multidisciplinary intervention programme with current standard management (advice and a physiotherapy appointment). Children and young people (CYP) were assessed for pain, function, coordination and strength at baseline, 3 and 12 months. Results: 119 children, aged 5–16 years, with symptomatic hypermobility were randomized to receive targeted multidisciplinary intervention (I) (n ¼ 59) or standard management (S) (n ¼ 60). Of these, 105 were followed to 12 months. There was a significant improvement in child and parent reported pain, coordination and strength. However, no added benefit could be shown from the intervention (Table 1). The number of children showing significant pain reduction (40%) was 27 (50.0%) (I) vs 21 (41.1%) (S). Those pain free at 12 months were 29 (56.9%) (I) vs 20 (45.5%) (S). The response was independent of the degree of hypermobility. Conclusion: This is the first RCT to compare a structured multidisciplinary intervention with standard care in symptomatic childhood hypermobility. The study demonstrates significant improvement

TABLE 1 The rate of change in primary and secondary outcomes over the 12-month follow-up period, this data includes analysis from multilevel modelling. Baseline score Outcome variable Child pain assessment (Wong-Baker Faces pain scale, 0–5, zero is the best) n ¼ 103, median (IQR) Parent observed pain assessment (0–100 VAS, zero is the best) n ¼ 105, mean (S.D.) Child health assessment questionnaire (CHAQ) (0–3, zero is the best) n ¼ 104, mean (S.D.) Child health 9 dimensional utility (CHU9D) (0–1, zero is the worst) n ¼ 104, mean (S.D.) Movement assessment battery for children (M-ABC) (0–100, zero is the worst) n ¼ 104, mean (S.D.) Grip strength (dynamometer) n ¼ 104, mean (S.D.)

Rate of change over 12 months (95% CI) Intervention group

2 (1–3)

Control group

1.42 (1.78, 1.06) 1.31

(1.75, 0.85)

35.90 (26.46) 6.09 (12.90, 0.73)

6.22

(13.62, 1.18)

0.82 (0.63)

þ0.02 (0.12, 0.16)

0.03

(0.13, 0.64)

0.85 (0.11)

þ0.02 (0.01, 0.04)

þ0.002 (0.02, 0.03)

34.56 (28.61) þ2.60 (2.92, 8.11)

þ8.51

(3.17, 13.86)

57.29 (28.30) þ4.55 (0.16, 8.94)

þ6.75

(2.85, 10.66)

IQR: interquartile range.

ß The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected]

ORAL PRESENTATIONS

among subjects but no additional benefit from targeted intervention. The findings emphasize the benefit of informed diagnosis and management according to clinical need, but highlight the difficulty in demonstrating subtle benefit from specific interventions without better tools for case definition and outcome assessment. Disclosure statement: The authors have declared no conflicts of interest. doi: 10.1093/rheumatology/keu491

ii3

correlation was seen between urinary VCAM-1, L-PGDS, C3 and urinary albumin-to-creatinine ratio (UAUC) (all P < 0.01). Urinary transferrin correlated significantly with C3, UAUC, ESR and dsDNA (all P < 0.01). Urinary NGAL levels were not significantly different between patient groups (P ¼ 0.142). See Table 1 below for a summary of results. Conclusion: We have shown that urinary VCAM-1, L-PGDS and transferrin are able to differentiate between active renal JSLE patients, non-active renal patients and HCs. Combinations of such biomarkers, as part of a urinary biomarker panel, have potential to improve LN monitoring and patient outcomes. Disclosure statement: The authors have declared no conflicts of interest.

OP3. DEVELOPING A URINARY BIOMARKER PANEL FOR MONITORING LUPUS NEPHRITIS DISEASE ACTIVITY Eve M. D. Smith1, Rachel Corkhill1, Angela Midgley1, Louise Watson1, Caroline Jones2, Stephen D. Marks3, Kjell Tullus3, Clarissa Pilkington4 and Michael W. Beresford1,5 1 Institute of Translational Medicine, University of Liverpool, Liverpool, 2 Department of Nephrolology, Alder Hey Children’s Hospital, Liverpool, 3Nephrology Unit, Great Ormond Street Hospital, London, 4 Paediatric Rheumatology Department, Great Ormond Street Hospital for Children Hospital, London and 5Department of Rheumatology, Alder Hey Children’s Hospital, Liverpool, UK Correspondence to: Eve M. D. Smith. E-mail: [email protected]

References 1. Hagelberg S, Lee Y, Bargman J et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635–42. 2. Suzuki M, Wiers K, Brooks EB et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res 2009;65:530–6. doi: 10.1093/rheumatology/keu492

Background: Up to 80% of children with juvenile-onset SLE (JSLE) develop LN, with the 5-year renal survival rate varying between 44% and 94% [1]. Conventional markers of JSLE disease activity fail to adequately predict impending LN flares. Recent studies have demonstrated that individual urinary biomarkers are not sufficient for monitoring LN disease activity [2]. Urinary levels of vascular cell adhesion molecule-1 (VCAM-1), lipocalin-like prostaglandin D synthase (L-PGDS), transferrin and neutrophil gelatinaseassociated lipocalin (NGAL) have been assessed, to determine if such biomarkers warrant inclusion within a LN urinary biomarker panel. Aims: To define urinary protein biomarkers that cross-sectionally differentiate between active LN, non-active LN and healthy controls (HCs). Methods: Urinary VCAM-1, L-PGDS and transferrin concentrations quantified by ELISA (R&D Systems Ltd, BioVendor, Genway, respectively). NGAL was measured using the commercially available Abbot Architect immunoassay. JSLE patients were classified as JSLE active renal or JSLE non-active renal based on the renal domain of the BILAG score. Healthy children, attending for non-inflammatory surgery, were recruited as controls. Data are expressed as median values and interquartile ranges (IQR). Kruskal–Wallis test used to compare biomarker levels between groups. Spearman’s rank correlation test was used for correlating biomarkers with clinical parameters. Results: 61 JSLE patients and 19 HCs were recruited. 24 (39%) were classed as JSLE active renal and 37 (60%) as JSLE non-active renal. JSLE patients had a median age of 16.5 years (range 10.07–21.91), and 72% were female. HCs had a median age of 12 years (range 4.0– 16.0), with 29% being female. All JSLE patients had a median of five ACR classification criteria (IQR 4–7). Urinary VCAM-1, L-PGDS and transferrin level were significantly higher in patients with active LN than in non-active renal patients and HCs (P ¼ 0.002–0.02). A significant

OP4. ENTHESITIS-RELATED ARTHRITIS IN ADOLESCENCE: DISEASE PHENOTYPE IN A LARGE COHORT Corinne Fisher1, Linda Suffield1, Anna Radziszewska1, Debajit Sen1 and Yiannis Ioannou1 1 Centre for Adolescent Rheumatology UCL, GOSH, UCLH, London, UK Correspondence to: Corinne Fisher. E-mail: [email protected] Background: Enthesitis-related arthritis (ERA) is a subtype of JIA as defined by the ILAR 2004 classification criteria. There are some similarities with adult spondyloarthropathy. However, the early clinical phenotype is often different with asymmetrical lower limb arthritis and enthesitis common at diagnosis. A proportion of patients go on to develop axial involvement but little is known about the natural history of this condition. Aims: Our study aimed to identify the clinical characteristics in a large cohort of patients, in particular those features associated with axial disease. Methods: Patients with ERA were identified from those attending the adolescent and young adult rheumatology clinics at University College London Hospital. A retrospective case note review was undertaken and a database of clinical manifestations, radiology and treatment was compiled. Results: 109 patients with ERA were identified [92 male (84.4%), 17 female (15.6%)] with a median age of onset of 11 years 1 month. 69% were HLA B27 positive. 61% had axial disease (confirmed on MRI) with 39% having peripheral arthritis and/or enthesitis only. Median followup was similar between the two groups (3 years 5 months vs 3 years 6 months). The most common clinical features were knee arthritis (75.2%), hip arthritis (67.9%), enthesitis (62.4%) and ankle arthritis (57.8%). The most frequent presenting symptoms were knee arthritis

TABLE 1 Urine biomarker concentrations in active LN, inactive LN and healthy controls Urinary protein biomarker

Active LN (n ¼ 24)

Inactive LN (n ¼ 37)

Healthy control (n ¼ 19)

Active vs inactive, P-value

Active vs HC, P-value

VCAM-1, ng/mgCra

16.65 (2.58–51.78)

2.3 (0.61–10.01)

2.4 (0.54–4.50)

0.002

0.003

L-PGDS, ng/mgCr

940.6 (291.3–1422.7)

312.1 (184.3–802.2)

396.5 (157.5–775.9)

0.005

0.014

Tf, ng/mgCr

5226.4 (678.4–48316.5)

1161.9 (772.5–1763.5)

680.9 (450.4–1415.4)

0.020

0.004

NGAL, ng/mgCr

21.6 (11-8–34.2)

12.5 (6.2–35.6)

10.0 (7.2–27.3)

Clinical parameters/urine biomarker correlations Parameter

r

P-value

C3 UAUC C3 UAUC C3 ESR UAUC dsDNA

–0.38 þ0.49 –0.43 þ0.44 –0.34 þ0.47 þ0.56 þ0.86